KATHMANDU, Oct 7: Enrollment for Sanofi and GSK’s Phase 3 efficacy trial of COVID-19 vaccine has started in Nepal.
Sanofi and GSK received approval for their Phase 3 clinical study in Nepal to assess the safety, efficacy and immunogenicity of their adjuvant recombinant-protein COVID-19 vaccine candidate.
Related story
Enrollment begins for Sanofi and GSK Phase 3 efficacy trial of...
The International Vaccine Institute (IVI), an international organization dedicated to the discovery, development and delivery of safe, effective and affordable vaccines, will conduct the Phase 3 clinical trial in Nepal, with an aim of enrolling 4,000 volunteers across 3 study sites in the country.
